Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745021 | 1.00 | CCR1 (0.38) | CCR1HSD11B1CCNA2CDK2USP5 | |
| SCHEMBL20598011 | 0.84 | GPR119 (0.45) | LMNATP53JAK3PTK2MEN1 | |
| SCHEMBL20025760 | 0.84 | ACVR1 (0.33) | JAK3PTK2ACVR1 | |
| SCHEMBL20598131 | 0.79 | USP5 (0.44) | CCR1HSD11B1CCNA2CDK2USP5 | |
| SCHEMBL19092433 | 0.78 | KHK (0.46) | HTR6JAK3PTK2PLATACVR1 | |
| SCHEMBL1135494 | 0.68 | CCR1 (0.79) | CCR1 | |
| SCHEMBL22325098 | 0.66 | LMNA (0.74) | HTR6LMNAHTTTSHRSMN1; SMN2 | |
| SCHEMBL19092139 | 0.62 | KMT2A (0.62) | USP5LMNAHTTRAB9ASMN1; SMN2 | |
| SCHEMBL26026399 | 0.62 | SCN9A (0.33) | CDK2HTR6 | |
| SCHEMBL16625191 | 0.62 | TNKS (0.57) | HSD11B1USP5LMNATRPV4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382621-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2025-12-18 | — | — | US | claimed |
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | claimed |
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | claimed |
| CN-110582488-A | Immune effector cell therapy with enhanced efficacy | 诺华股份有限公司 | 2019-12-17 | — | — | CN | claimed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | claimed |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | claimed |
| US-20250382621-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| CN-110582488-A | Immune effector cell therapy with enhanced efficacy | 诺华股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | CCR1 166/4885HSD11B1 2395/4885CCNA2 2917/4885 |
| US-20250382621-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | CCR1 199/4885HSD11B1 2664/4885CCNA2 3082/4885 |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | CCR1 179/4885HSD11B1 2558/4885CCNA2 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.